PTC Therapeutics, Inc. - PTCT STOCK NEWS

PTC Therapeutics announced that the FDA has granted priority review for its Evrysdi (risdiplam) to treat pre-symptomatic infants under 2 months with spinal muscular atrophy (SMA). If approved, Evrysdi will be the first at-home treatment for this vulnerable group. Interim data from the RAINBOWFISH study showed that 80% of treated infants achieved key motor milestones within 12 months. The company emphasizes the need for early treatment in SMA cases, reinforcing the significance of Evrysdi in improving patients' lives.

PTC Therapeutics (NASDAQ: PTCT) has announced the launch of the eighth annual STRIVE™ awards program to support initiatives for the Duchenne muscular dystrophy community. Grants will be awarded to patient advocacy organizations focusing on Innovation or Transition to Adulthood. The application process is open until March 18, 2022, with recipients announced in September. The STRIVE program has funded over 35 initiatives across 20 countries since its inception, enhancing awareness and support for Duchenne patients.

PTC Therapeutics, Inc. (NASDAQ: PTCT) announced on Jan. 7, 2022, the approval of non-statutory stock options for 26 new employees, totaling 18,255 shares, along with 10,675 restricted stock units (RSUs). These awards aim to incentivize new hires as part of their employment compensation, following NASDAQ's inducement grant exception. All stock options have an exercise price of $38.10 per share and vest over four years, contingent on continued service. This initiative reflects PTC's commitment to attracting talent for its rare disorder therapies.

PTC Therapeutics, Inc. (NASDAQ: PTCT) has launched its 2022 Talent Pipeline Program, a global initiative aimed at providing recent college graduates with real-world job experiences. The program, which begins accepting applications on Feb. 11, 2022, will include around 30 Fellows who will receive mentorship, job coaching, and leadership training throughout the year. Successful participants will earn a Certificate of Completion and will be considered for future positions. The initiative aims to attract and retain top talent while enhancing PTC's organizational capabilities.

PTC Therapeutics presented an update on its commercial progress and R&D pipeline at the 40th J.P. Morgan Healthcare Conference on January 10, 2022. The company reported a 29% growth in net product revenue to $429 million in 2021, driven by its Duchenne muscular dystrophy (DMD) franchise. Key milestones for 2022 include expected results from clinical studies for Translarna and vatiquinone, alongside a financial guidance projecting revenues between $700 million and $750 million. The company holds approximately $773 million in cash as of year-end 2021.

PTC Therapeutics announced that Waylivra™ (volanesorsen) has received Category 1 classification from Brazil's CMED, making it the only treatment for familial chylomicronemia syndrome (FCS) available in the country. This classification recognizes its greater efficacy over current treatments and allows for international pricing. Furthermore, PTC submitted an application to ANVISA for Waylivra’s approval for familial partial lipodystrophy (FPL), potentially marking the first approved treatment for FPL globally. A decision from ANVISA is expected in the latter half of 2022.

PTC Therapeutics will present a company overview at the 40th Annual J.P. Morgan Virtual Healthcare Conference on January 10, 2022, at 7:30 a.m. EST. The live webcast can be accessed on PTC's Investor Events and Presentations page and will be archived for 30 days. PTC Therapeutics focuses on developing and commercializing medicines for rare disorders, with a commitment to providing access to innovative treatments for patients in need.

PTC Therapeutics (PTCT) announced the publication in Nature Communications detailing a novel splicing mechanism from its Huntington Disease (HD) program. This mechanism selectively lowers huntingtin protein levels via innovative splicing modifiers. CEO Stuart W. Peltz highlighted the breakthrough's potential to regulate gene expression, benefiting various diseases. HD affects around 45,000 individuals in the U.S., with no existing treatments targeting its underlying cause. PTC aims to leverage its splicing platform for new therapies, enhancing its pipeline of medicines for rare disorders.

PTC Therapeutics announced that its oral therapy Evrysdi^® (risdiplam) has received prestigious awards for its innovation and life-saving effects. Recognized as the 2022 Drug Discovery of the Year by the British Pharmacological Society and the 2021 Drug Discovery Prize by the Society for Medicines Research, Evrysdi aims to treat spinal muscular atrophy (SMA) by enhancing SMN protein levels. The drug is commercialized by Roche and Genentech in the U.S., showcasing PTC's commitment to addressing unmet medical needs through innovative therapies.